169 related articles for article (PubMed ID: 20572801)
1. Sustained, durable responses with alemtuzumab in refractory angioimmunoblastic T-cell lymphoma.
Amengual JE; Raphael BG
Leuk Lymphoma; 2010 Jul; 51(7):1347-50. PubMed ID: 20572801
[No Abstract] [Full Text] [Related]
2. Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphoma.
Dunleavy K; Wilson WH
Leuk Lymphoma; 2010 Sep; 51(9):1583-4. PubMed ID: 20795788
[No Abstract] [Full Text] [Related]
3. Sustained remission from angioimmunoblastic T-cell lymphoma induced by alemtuzumab.
Halene S; Zieske A; Berliner N
Nat Clin Pract Oncol; 2006 Mar; 3(3):165-8; quiz 169. PubMed ID: 16520806
[TBL] [Abstract][Full Text] [Related]
4. Rapid and durable molecular response of refractory T-cell large granular lymphocyte leukemia after alemtuzumab treatment.
Monjanel H; Hourioux C; Arbion F; Colombat P; Lissandre S; Regner MP; Senecal D
Leuk Res; 2010 Aug; 34(8):e197-9. PubMed ID: 20211489
[No Abstract] [Full Text] [Related]
5. Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study.
Kim SJ; Kim K; Kim BS; Suh C; Huh J; Ko YH; Kim WS
Ann Oncol; 2009 Feb; 20(2):390-2. PubMed ID: 19211502
[No Abstract] [Full Text] [Related]
6. Alemtuzumab in lymphoproliferate disorders.
Dearden CE
Rev Clin Exp Hematol; 2002 Dec; 6(4):435-48; discussion 449-50. PubMed ID: 12823782
[No Abstract] [Full Text] [Related]
7. Alemtuzumab for refractory celiac disease in a patient at risk for enteropathy-associated T-cell lymphoma.
Vivas S; Ruiz de Morales JM; Ramos F; Suárez-Vilela D
N Engl J Med; 2006 Jun; 354(23):2514-5. PubMed ID: 16760460
[No Abstract] [Full Text] [Related]
8. Treatment of patients with refractory diffuse large B-cell lymphoma or mantle cell lymphoma with alemtuzumab, alone or in combination with cytotoxic chemotherapy.
Yi JH; Kim SJ; Ko YH; Kim WS
Leuk Lymphoma; 2011 Feb; 52(2):317-20. PubMed ID: 21067447
[No Abstract] [Full Text] [Related]
9. The role of alemtuzumab in the management of T-cell malignancies.
Dearden C
Semin Oncol; 2006 Apr; 33(2 Suppl 5):S44-52. PubMed ID: 16720203
[TBL] [Abstract][Full Text] [Related]
10. Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.
Ferrajoli A; Wierda WG; LaPushin R; O'Brien SM; Faderl S; Browning ML; Keating MJ
Eur J Haematol; 2008 Apr; 80(4):296-8. PubMed ID: 18182081
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of alemtuzumab and gemcitabine in a patient with enteropathy-type T-cell lymphoma.
Soldini D; Mora O; Cavalli F; Zucca E; Mazzucchelli L
Br J Haematol; 2008 Jul; 142(3):484-6. PubMed ID: 18510686
[No Abstract] [Full Text] [Related]
12. Alemtuzumab in T-cell malignancies.
Dearden CE; Matutes E; Catovsky D
Med Oncol; 2002; 19 Suppl():S27-32. PubMed ID: 12180489
[TBL] [Abstract][Full Text] [Related]
13. Treatment of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma with fludarabine.
Tsatalas C; Margaritis D; Pantelidou D; Spanudakis E; Kaloutsi V; Bourikas G
Acta Haematol; 2003; 109(2):110. PubMed ID: 12624498
[No Abstract] [Full Text] [Related]
14. Alemtuzumab (Campath 1H) as successful salvage therapy for recurrent steroid-resistant heart transplant rejection.
Woodside KJ; Lick SD
J Heart Lung Transplant; 2007 Jul; 26(7):750-2. PubMed ID: 17613409
[TBL] [Abstract][Full Text] [Related]
15. Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with alpha/beta hepatosplenic T-cell non-Hodgkin's lymphoma.
Chanan-Khan A; Islam T; Alam A; Miller KC; Gibbs J; Barcos M; Czuczman MS; Paplham P; Hahn T; McCarthy P
Leuk Lymphoma; 2004 Aug; 45(8):1673-5. PubMed ID: 15370223
[TBL] [Abstract][Full Text] [Related]
16. Receptor-directed therapy of T-cell leukemias and lymphomas.
Morris JC; Waldmann TA; Janik JE
J Immunotoxicol; 2008 Apr; 5(2):235-48. PubMed ID: 18569395
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment with mogamulizumab of refractory/relapsed angioimmunoblastic T-cell lymphoma following autologous stem cell transplantation.
Oka S; Ono K; Nohgawa M
Leuk Lymphoma; 2019 Jun; 60(6):1595-1597. PubMed ID: 30732495
[No Abstract] [Full Text] [Related]
18. Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia.
Rosenblum MD; LaBelle JL; Chang CC; Margolis DA; Schauer DW; Vesole DH
Blood; 2004 Mar; 103(5):1969-71. PubMed ID: 14976065
[No Abstract] [Full Text] [Related]
19. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center.
Querfeld C; Mehta N; Rosen ST; Guitart J; Rademaker A; Gerami P; Kuzel TM
Leuk Lymphoma; 2009 Dec; 50(12):1969-76. PubMed ID: 19860617
[TBL] [Abstract][Full Text] [Related]
20. Treatment with alemtuzumab in a case of refractory primary cutaneous CD30-negative CD8-positive cytotoxic large T-cell lymphoma.
Gutierrez A; Rodriguez J; Ramos R; Gines J; Sampol A; Galmes B; Besalduch J
Eur J Haematol; 2004 May; 72(5):377-8. PubMed ID: 15059077
[No Abstract] [Full Text] [Related]
[Next] [New Search]
